Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	280
Overall Study	STARTED	Aliskiren 300 mg	271
Overall Study	STARTED	Valsartan 320 mg	269
Overall Study	STARTED	Aliskiren/Valsartan 300/320 mg	281
Overall Study	COMPLETED	Placebo	228
Overall Study	COMPLETED	Aliskiren 300 mg	201
Overall Study	COMPLETED	Valsartan 320 mg	215
Overall Study	COMPLETED	Aliskiren/Valsartan 300/320 mg	214
Overall Study	NOT COMPLETED	Placebo	52
Overall Study	NOT COMPLETED	Aliskiren 300 mg	70
Overall Study	NOT COMPLETED	Valsartan 320 mg	54
Overall Study	NOT COMPLETED	Aliskiren/Valsartan 300/320 mg	67

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00409578/flow